This work provides new insights into the development of cancer therapeutics, suggesting that a small molecule inhibitor of Wee1 kinase should be efficacious against a large number of p53 inactive solid tumors as a single agent and provide a safe therapeutic window in the p53 wild-type tissues of patients. This evidence concerns the gene TP53 and cancer.